Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Between Casgevy's long-term potential and the company's innovative pipeline, CRISPR Therapeutics could eventually recover and ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and ...

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Vertex Pharmaceuticals Incorporated presented updated clinical data for zimislecel – VX-880) – its investigational stem ...

Flyer of the 12th Annual Warrior Convention A Sickle Cell Family Reunion of Warriors, Advocates, and Caregivers ORLANDO, FL, UNITED ...